Evidence map›Paper›PMID 38928334›Full record

ArticleInternational journal of molecular sciences2024

An Efficient Method for Vault Nanoparticle Conjugation with Finely Adjustable Amounts of Antibodies and Small Molecules.

Giulia Tomaino, Camilla Pantaleoni, Annalisa D'Urzo, Carlo Santambrogio, Filippo Testa, Matilde Ciprandi, Davide Cotugno, Gianni Frascotti, Marco Vanoni, Paolo Tortora

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Special Issue on Nanoparticles in Nanobiotechnology and Nanomedicine.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giulia TomainoDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.ORCID 0000-0001-5908-4665
Camilla PantaleoniDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.
Annalisa D'UrzoDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.
Carlo SantambrogioDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.ORCID 0000-0003-3986-6971
Filippo TestaDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.ORCID 0000-0002-9234-7778
Matilde CiprandiDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.
Davide CotugnoDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.
Gianni FrascottiDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.ORCID 0000-0002-5963-7650
Marco VanoniDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.ORCID 0000-0002-8690-2587
Paolo TortoraDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.ORCID 0000-0001-5234-601X

Funding

Italian Ministry of University and Research (PRIN 2017: "Development of a biotechnological nanoparticle platform for the delivery of antitumor therapies using Patient-Derived Organoid Library of Breast Cancer"). 2017E3A2NR
6 · The paper itself

Abstract

Vaults are eukaryotic ribonucleoproteins consisting of 78 copies of the major vault protein (MVP), which assemble into a nanoparticle with an about 60 nm volume-based size, enclosing other proteins and RNAs. Regardless of their physiological role(s), vaults represent ideal, natural hollow nanoparticles, which are produced by the assembly of the sole MVP. Here, we have expressed in

Indexed as

NanoparticlesTrastuzumabVault Ribonucleoprotein ParticlesAntibodies, MonoclonalCell Line, TumorCetuximabHumansImmunoconjugatesMajor Vault ProteinAntibodies, MonoclonalCetuximabImmunoconjugatesMajor Vault ProteinTrastuzumabVault Ribonucleoprotein Particlesantibody-mediated targetingFc antibody portionKomagataella phaffii expression systemliquid chromatography/mass spectrometrymajor vault proteinsurface plasmon resonancevault nanoparticle

Identifiers

PMID38928334
PMCPMC11203631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.